Pelitinib - Wyeth
Alternative Names: EKB-569Latest Information Update: 05 Nov 2023
At a glance
- Originator Wyeth
- Class Antineoplastics; Organic chemicals; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 16 Oct 2009 Wyeth has been acquired by Pfizer
- 08 Dec 2004 Data presented at the 29th Congress of the European Society for Medical Oncology (ESMO-2004) have been added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections
- 22 Apr 2004 Phase-II clinical trials in Colorectal cancer in USA (PO)